Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew S Davids

Showing results (141-150 of 225) with videos related to

Pageof 23
Sort By:
Blood Advances|October 7, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomasAlberto J Arribas, Sara Napoli, Eugenio Gaudio, et al.
Blood Advances|September 25, 2024
Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemiaAbi Vijenthira, Virginia O Volpe, Aswin Sekar, et al.
Leukemia|November 7, 2021
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemiaDeepti Gadi, Alec Griffith, Svitlana Tyekucheva, et al.
Blood Advances|August 13, 2021
Activity of mRNA COVID-19 vaccines in patients with lymphoid malignanciesJennifer L Crombie, Amy C Sherman, Chi-An Cheng, et al.
Haematologica|May 7, 2013
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaJennifer R Brown, Bradley Messmer, Lillian Werner, et al.
Blood Advances|April 11, 2019
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemiaBenjamin L Lampson, Haesook T Kim, Matthew S Davids, et al.
The Lancet. Haematology|December 19, 2018
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b studyMatthew S Davids, Haesook T Kim, Alyssa Nicotra, et al.
The Lancet. Oncology|December 17, 2017
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trialJeffrey A Jones, Anthony R Mato, William G Wierda, et al.
Blood|April 13, 2016
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Jing Deng, John F Seymour, et al.
The Lancet. Oncology|September 17, 2021
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S Davids, Benjamin L Lampson, Svitlana Tyekucheva, et al.
Pageof 23

Showing results (141-150 of 225) with videos related to

Sort By:
Pageof 23
Blood Advances|October 7, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomasAlberto J Arribas, Sara Napoli, Eugenio Gaudio, et al.
Blood Advances|September 25, 2024
Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemiaAbi Vijenthira, Virginia O Volpe, Aswin Sekar, et al.
Leukemia|November 7, 2021
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemiaDeepti Gadi, Alec Griffith, Svitlana Tyekucheva, et al.
Blood Advances|August 13, 2021
Activity of mRNA COVID-19 vaccines in patients with lymphoid malignanciesJennifer L Crombie, Amy C Sherman, Chi-An Cheng, et al.
Haematologica|May 7, 2013
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaJennifer R Brown, Bradley Messmer, Lillian Werner, et al.
Blood Advances|April 11, 2019
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemiaBenjamin L Lampson, Haesook T Kim, Matthew S Davids, et al.
The Lancet. Haematology|December 19, 2018
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b studyMatthew S Davids, Haesook T Kim, Alyssa Nicotra, et al.
The Lancet. Oncology|December 17, 2017
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trialJeffrey A Jones, Anthony R Mato, William G Wierda, et al.
Blood|April 13, 2016
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Jing Deng, John F Seymour, et al.
The Lancet. Oncology|September 17, 2021
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S Davids, Benjamin L Lampson, Svitlana Tyekucheva, et al.
Pageof 23